The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2025 | Predictive biomarkers & neoadjuvant platforms in cancer treatment personalization
Merrick Ross, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of identifying predictive biomarkers to personalize cancer treatment. He explains how a combination of markers, such as pathologic response and circulating tumor DNA (ctDNA), can help determine prognosis and potentially reduce the need for extensive therapy. Dr Ross highlights promising research in colon cancer and lung cancer, emphasizing the role of the neoadjuvant platform in advancing biomarker discovery. This interview took place at the PRIMO 2025 congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
